Of particular interest is the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to address STZ-induced changes following intraventricular administration
A good plan includes lab tests and doctor checks to make sure its working right
Here's a week of GLP-1-friendly breakfasts that rotate between smoothies, oat bowls, and savory options
As a GLP-1 receptor agonist, retatrutide may carry similar risks to semaglutide , which include: Acute pancreatitis Diabetic retinopathy complications (diabetes-related vision changes) Hypoglycemia (low blood sugar), especially when used with insulin Kidney or gallbladder issues Severe gastrointestinal reactions Allergic reactions Pulmonary aspiration during general anesthesia or deep sedation All GLP-1 receptor agonists carry a boxed warning for thyroid tumors based on animal studies
Cycle between abdomen, thighs, and glutes
GLP-1s are injectables, and you have to keep taking them